Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Mutational drivers of thyroid cancer

IV IFHNOS Global CME on Head and Neck Cancers

Published: 24 Nov 2016

Views: 2237

Rating:

Save

Dr Alexsandr Lavrov - N.I.Pirogov Russian National Research Medical University, Moscow, Russia

Dr Lavrov speaks with ecancertv at the IFHNOS 2016 session in Moscow about molecular genetics aiding in diagnosis and treatment of thyroid cancer.

He outlines the processes by which mutational aberrations can be detected, and how to cope with the wealth of data rendered by next-generation sequencing.

Related Videos

Predicting tumour mutations from pathology images may help increase...

Dr Rom Leidner - Providence Cancer Institute, Portland, USA

Predicting tumour mutations from pathology images may help increase personalised medicine utilisation ( Dr Rom Leidner - Providence Cancer Institute, Portland, USA )

ESMO 2024: Optimising the personalisation of prostate cancer treatment

Prof Alison Birtle, Dr Alejo Rodríguez-Vida, Dr Pasquale Rescigno and Prof...

ESMO 2024: Optimising the personalisation of prostate cancer treatment ( Prof Alison Birtle, Dr Alejo Rodríguez-Vida, Dr Pasquale Rescigno and Prof Gunhild von Amsberg )

Best practice in HRRm testing in patients with metastatic prostate cancer

Prof Martin Schostak, Dr Alexander Wyatt, Prof Charles Ryan and Dr Emmanuel...

Best practice in HRRm testing in patients with metastatic prostate cancer ( Prof Martin Schostak, Dr Alexander Wyatt, Prof Charles Ryan and Dr Emmanuel Antonarakis )

Multiple myeloma in a resource constrained setting

Dr Henry Ddungu - Uganda Cancer Institute, Kampala, Uganda

Multiple myeloma in a resource constrained setting ( Dr Henry Ddungu - Uganda Cancer Institute, Kampala, Uganda )

Management of prostate cancer in Africa: Looking to the future

Dr Timothy Rebbeck - Dana-Farber Cancer Institute, Boston, USA

Management of prostate cancer in Africa: Looking to the future ( Dr Timothy Rebbeck - Dana-Farber Cancer Institute, Boston, USA )

Choosing Wisely in pathology

Dr Angela Mlole - Ocean Road Cancer Institute, Dar es Salaam, Tanzania

Choosing Wisely in pathology ( Dr Angela Mlole - Ocean Road Cancer Institute, Dar es Salaam, Tanzania )

Choosing Wisely in radiology Tanzania

Dr Revelian Iramu - Ocean Road Cancer Institute, Dar es Salaam, Tanzania

Choosing Wisely in radiology Tanzania ( Dr Revelian Iramu - Ocean Road Cancer Institute, Dar es Salaam, Tanzania )

Li-Fraumeni syndrome-associated dimer-forming mutant p53 promotes...

Dr Joshua Choe - Columbia University, New York City, USA

Li-Fraumeni syndrome-associated dimer-forming mutant p53 promotes transactivation-independent mitochondrial cell death ( Dr Joshua Choe - Columbia University, New York City, USA )

Combination of camonsertib plus PARPi shows clinical activity in DDR-aberrant...

Dr Timothy Yap - The University of Texas MD Anderson Cancer Center, Houston, USA

Combination of camonsertib plus PARPi shows clinical activity in DDR-aberrant tumours ( Dr Timothy Yap - The University of Texas MD Anderson Cancer Center, Houston, USA )

More from ecancer